[go: up one dir, main page]

WO2007031277A3 - Moyens et procedes permettant de diagnostiquer l'endometriose - Google Patents

Moyens et procedes permettant de diagnostiquer l'endometriose Download PDF

Info

Publication number
WO2007031277A3
WO2007031277A3 PCT/EP2006/008877 EP2006008877W WO2007031277A3 WO 2007031277 A3 WO2007031277 A3 WO 2007031277A3 EP 2006008877 W EP2006008877 W EP 2006008877W WO 2007031277 A3 WO2007031277 A3 WO 2007031277A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
endometriosis
diagnosing endometriosis
molecules interacting
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008877
Other languages
English (en)
Other versions
WO2007031277A2 (fr
Inventor
Walter Tschugguel
Cristina Rubiolo
Andrea Kolbus
Ljubomir Paucz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Wien
Original Assignee
Medizinische Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Wien filed Critical Medizinische Universitaet Wien
Priority to EP06791999A priority Critical patent/EP1931993A2/fr
Publication of WO2007031277A2 publication Critical patent/WO2007031277A2/fr
Publication of WO2007031277A3 publication Critical patent/WO2007031277A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne des moyens et des procédés permettant de déterminer la présence probable d'endométriose chez un sujet femelle. En outre, cette invention concerne des trousses permettant de mettre en oeuvre les procédés susmentionnés. Cette invention concerne également des nouvelles utilisations de molécules de liaison interagissant et/ou se liant spécifiquement à l'ezrine et/ou de molécules de liaison interagissant et/ou se liant spécifiquement avec le substrat 1 du récepteur de l'insuline (IRS-1) pour la préparation de compositions permettant de diagnostiquer l'endométriose.
PCT/EP2006/008877 2005-09-14 2006-09-12 Moyens et procedes permettant de diagnostiquer l'endometriose Ceased WO2007031277A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06791999A EP1931993A2 (fr) 2005-09-14 2006-09-12 Moyens et procedes permettant de diagnostiquer l'endometriose

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATA1519/2005 2005-09-14
AT15192005 2005-09-14
US83510506P 2006-08-03 2006-08-03
US60/835,105 2006-08-03

Publications (2)

Publication Number Publication Date
WO2007031277A2 WO2007031277A2 (fr) 2007-03-22
WO2007031277A3 true WO2007031277A3 (fr) 2007-06-21

Family

ID=37606092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008877 Ceased WO2007031277A2 (fr) 2005-09-14 2006-09-12 Moyens et procedes permettant de diagnostiquer l'endometriose

Country Status (2)

Country Link
EP (1) EP1931993A2 (fr)
WO (1) WO2007031277A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11287425B2 (en) 2009-04-22 2022-03-29 Juneau Biosciences, Llc Genetic markers associated with endometriosis and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140126A1 (fr) * 2008-05-14 2009-11-19 Juneau Biosciences, Llc Procédé d’administration d’un agent thérapeutique
DE102012002929A1 (de) * 2012-02-14 2013-08-14 Jürgen Lewald Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose
RU2675525C1 (ru) * 2017-12-12 2018-12-19 Публичное акционерное общество "СИБУР Холдинг" Сополимеры сопряженных диенов и винилароматических мономеров и способ их получения. Резиновые смеси на основе указанных сополимеров

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063116A2 (fr) * 1998-06-04 1999-12-09 Reprogen, Inc. Utilisation de la prothymosine dans le diagnostic et le traitement de l'endometriose
WO2000043789A1 (fr) * 1999-01-25 2000-07-27 Procrea Biosciences Inc. Procede et kit de diagnostic pour le diagnostic de l'endometriose
WO2004016739A2 (fr) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Modulation cellulaire au moyen d'une proteine de cytosquelette
US20040162257A1 (en) * 2001-06-14 2004-08-19 Gene Signal, A Corporation Of France Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
WO2006015079A2 (fr) * 2004-07-27 2006-02-09 Yale University Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063116A2 (fr) * 1998-06-04 1999-12-09 Reprogen, Inc. Utilisation de la prothymosine dans le diagnostic et le traitement de l'endometriose
WO2000043789A1 (fr) * 1999-01-25 2000-07-27 Procrea Biosciences Inc. Procede et kit de diagnostic pour le diagnostic de l'endometriose
US20040162257A1 (en) * 2001-06-14 2004-08-19 Gene Signal, A Corporation Of France Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
WO2004016739A2 (fr) * 2002-08-01 2004-02-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Modulation cellulaire au moyen d'une proteine de cytosquelette
US20040105860A1 (en) * 2002-08-01 2004-06-03 Losordo Douglas W. Cell modulation using a cytoskeletal protein
WO2006015079A2 (fr) * 2004-07-27 2006-02-09 Yale University Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
COLOMBATTI ALFONSO ET AL: "Differential expression of IRS-1 and IRS-2 in uterine leiomyosarcomas with distinct oncogenic phenotypes: Lack of correlation with downstream signaling events.", SARCOMA, vol. 6, no. 3, September 2002 (2002-09-01), pages 89 - 96, XP002425254, ISSN: 1357-714X *
DATABASE Geneseq [online] 7 April 2003 (2003-04-07), "Amino acid sequence of human insulin receptor substrate-1.", XP002425283, retrieved from EBI accession no. GSP:ABB99797 Database accession no. ABB99797 *
DHEENADAYALU KAVITHA ET AL: "Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosis.", FERTILITY AND STERILITY OCT 2002, vol. 78, no. 4, October 2002 (2002-10-01), pages 825 - 829, XP002416051, ISSN: 0015-0282 *
HARRISON G M ET AL: "DISTRIBUTION AND EXPRESSION OF CD44 ISOFORMS AND EZRIN DURING PROSTATE CANCER-ENDOTHELIUM INTERACTION", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 21, no. 5, November 2002 (2002-11-01), pages 935 - 940, XP009065619, ISSN: 1019-6439 *
NAGAMANI ET AL: "Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 179, no. 1, July 1998 (1998-07-01), pages 6 - 12, XP005691528, ISSN: 0002-9378 *
OHTANI K ET AL: "Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma", CANCER LETTERS, NEW YORK, NY, US, vol. 179, no. 1, 8 May 2002 (2002-05-08), pages 79 - 86, XP002378867, ISSN: 0304-3835 *
OHTANI K ET AL: "Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells", CANCER LETTERS, NEW YORK, NY, US, vol. 147, no. 1-2, 1 December 1999 (1999-12-01), pages 31 - 38, XP002378865, ISSN: 0304-3835 *
SURMACZ W ET AL: "OVEREXPRESSION OF INSULIN RECEPTON SUBSTRATE 1 (IRS-1) IN THE HUMAN BREAST CANCER CELL LINE MCF-7 INDUCES LOSS OF AND TRANSFORMATION 1", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 1, no. 11, 1 November 1995 (1995-11-01), pages 1429 - 1436, XP000560324, ISSN: 1078-0432 *
WU X ET AL: "Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls.", FERTILITY AND STERILITY SEP 2000, vol. 74, no. 3, September 2000 (2000-09-01), pages 564 - 572, XP002415873, ISSN: 0015-0282 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11287425B2 (en) 2009-04-22 2022-03-29 Juneau Biosciences, Llc Genetic markers associated with endometriosis and use thereof

Also Published As

Publication number Publication date
WO2007031277A2 (fr) 2007-03-22
EP1931993A2 (fr) 2008-06-18

Similar Documents

Publication Publication Date Title
WO2010039809A3 (fr) Amorces et sondes pour la détection du papillomavirus humain et des séquences de bêta globine humaine dans des échantillons test
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
WO2008063783A3 (fr) Biomarqueurs liés à un âge métabolique et leurs procédés d'utilisation
WO2010102251A3 (fr) Protéines de liaison à il-17
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
EP1984726A4 (fr) Procedes, melanges, kits et compositions appartenant à une determination de substances a analyser
WO2007062090A8 (fr) Procedes et compositions lies a des analyses de lymphocytes b
MX345092B (es) Anticuerpos anti-tau humanos,.
AU2011343161A8 (en) Human anti-SOD1 antibodies
WO2014100600A3 (fr) Anticorps anti-tau humains
WO2007092353A3 (fr) Profils de biomarqueurs pour la grossesse, méthodes et compositions associées
WO2013061163A3 (fr) Molécules de liaison spécifiques de tdp-43
WO2008157264A3 (fr) Procédés combinés pour la détection de l'aneuploïdie chromosomique
WO2011062803A3 (fr) Immuno-essais multiplex pour hémoglobine, variations d'hémoglobine et formes glycatées
WO2008024473A3 (fr) Cartographie d'interactions génomiques
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2010033279A3 (fr) <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
WO2010115745A3 (fr) Biomarqueurs, procédés et kits de diagnostic de la polyarthrite rhumatoïde
WO2009015284A8 (fr) Protéines de liaison à un antigène de récepteur d'il-18
WO2010005982A3 (fr) Biomarqueurs multiplexés de résistance à l'insuline
WO2009015359A3 (fr) Sondes spécifiques des chromosomes hautement visibles et procédés associés
WO2008089072A3 (fr) Méthode d'établissement de profils protéomiques pour le diagnostic et la surveillance d'états pathologiques, le criblage de compositions et la surveillance thérapeutique
WO2008152656A3 (fr) Variants génétiques sur chr 15q24 servant de marqueurs et destinés à être utilisés dans le diagnostic, le pronostic et le traitement du syndrome d'exfoliation et du glaucome
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2007047408A3 (fr) Application de signature promac

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006791999

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006791999

Country of ref document: EP